Intellect and Lonza team up to develop antibody-drug conjugate

09/30/2012 | Pharmaceutical Business Review Online

Lonza and Intellect Neurosciences entered a deal to develop and manufacture Conjumab-A, an antibody-drug conjugate. Lonza will provide preclinical study material for drug optimization and selection for the conjugate, which targets age-related macular degeneration with potential applications for Alzheimer's disease.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief: